Man, 28, dies suddenly after collapsing during Great Bristol Run half marathon
A MAN has died after collapsing during the Great Bristol Run half marathon.
Jon Devereux, a 28-year-old runner collapsed during the event on Sunday.
His cause of death is unknown.
A statement from the Great Run Company said: "It is with great sadness that The Great Run Company confirms the death of a participant at the Great Bristol Run on Sunday, 11 May 2025.
"Jon Devereux, aged 28, collapsed during the event, received immediate medical treatment, and later passed away in hospital.
"His next of kin have been informed.
"The entire team involved in organising the Great Bristol Run extends their heartfelt condolences to Mr Devereux's family and friends.
"In accordance with the wishes of the family, no further details will be released.
"The cause of death will be determined later, pending medical examination."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
9 minutes ago
- The Independent
Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
Parents whose sons are losing the ability to walk have described the 'nightmare' battle they face with the NHS to access a free drug. The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'
TTG
39 minutes ago
- TTG
'It's comfortable and cosy': why working from bed is key to this agent's success
A travel agency owner has called for more compassion for homeworkers, arguing that she manages her company more efficiently from her house – and indeed her bed – than she ever could from an office. Paula Hansen runs World Accessible Holidays, which specialises in travel for disabled clients, entirely from her home in Wales. Like many agents, she believes a remote model enables her to maintain a healthier work-life balance and be overall more productive. But for Hansen, homeworking isn't just a perk – it's a necessity. The mother-of-one lives with fibromyalgia, a chronic disorder that causes pain in muscles and soft tissues all over the body. Other symptoms include fatigue, brain fog and sleep disturbances, all of which can significantly affect the individual's ability to work – and makes working from an office almost impossible. In 2023, 136,000 claimants of PIP (Personal Independence Payment) listed fibromyalgia as their main disabling condition. Many people in employment may also require additional sick leave and/or reduced hours, due to the severe and often volatile nature of their symptoms. But Hansen is determined not to let her fibromyalgia limit her potential as a business woman. Three years on from her diagnosis, she has developed a sturdy kit of tools for maintaining her productivity – including working from bed. 'Why shouldn't you work from bed?' Hansen tells TTG Luxury. 'It's comfortable and cosy, and you're probably working more effectively because you're relaxed.' The self-proclaimed 'bedpreneur' says that working from bed is also preferable to a desk, which tends to flare up her symptoms: 'All of the pain from my fibromyalgia is from the hips upwards, so my back will hurt if I'm sitting on a chair for too long.' Hansen's work hours are also atypical, beginning at around 10am and ending at nearly midnight. 'My pain levels are highest in the morning, so I'll do some hours after 10am, and then if I'm tired, I'll go and have a sleep, and then resume work when I wake up,' she explains. 'So it is more like a nine to 11 schedule, with lots of sleep breaks in between.' She also uses meditation and ice packs, along with painkillers when necessary, to further alleviate her symptoms. 'Why shouldn't you work from bed? It's comfortable and cosy' As well as helping her to manage pain more effectively, working from home has also been hugely beneficial for Hansen's concentration. Without the usual office disruptions, she says she can focus for longer and thus, complete tasks faster. This lack of distractions can be especially valuable for people with fibromyalgia, 80% of whom will experience issues with memory and attention. While Hansen's condition has undoubtedly made work more challenging, it has also instilled in her a great deal of empathy for her clients. The Cardiff native knows all too well the obstacles of travelling with mobility issues; as well as causing extreme tiredness, her fibromyalgia prevents her from sitting in one position for extended periods of time, which makes driving and flying particularly difficult. Hansen also has a teenage son with cerebral palsy, a neurological condition that causes muscle weakness and impaired mobility. While Evan can walk short distances, he requires a wheelchair and is unable to travel without assistance. Flying can be especially 'nightmarish', says Hansen, due to the lack of consideration from other passengers boarding the plane. It's this first-hand experience of disability that has given her the determination to continue advocating for disabled travellers – even when she's in severe pain. Hansen arranges all types of trips for her clients, from city breaks and beach holidays to safaris and honeymoons. To achieve this, she partners with specialist suppliers who can provide medical equipment, adapted transport and accessible accommodation. The disability of her customers varies, but each one has a dream of travelling without barriers. For many, it's their first holiday after a serious illness or accident. The additional requirements create extra work for Hansen, but having witnessed the life-changing power of travel for individuals with disabilities, she says 'it's all worthwhile'. 'When you have a client tell you they've gotten into the sea for the first time because you've recommended a hotel with a sea track, that is much better than just someone saying, 'I've had a great holiday,'' she explains. 'It's so rewarding.'
BBC News
2 hours ago
- BBC News
Cancer: World-first 'Trojan horse' therapy to be given on NHS
A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world can halt the blood cancer myeloma for nearly three times longer than current drug is an advanced form of chemotherapy that hits cancer with a bigger dose, while reducing Silvester, one of the first people to get it, says the therapy has been "life-changing" and he's now planning history-themed adventures. Myeloma – also known as multiple myeloma – affects part of the immune system called plasma cells. These are made in the spongey bone marrow in the centre of our who is 60 and from Sheffield, was diagnosed nearly two years ago after the cancer led to broken bones in his had a bone marrow transplant last year, but relapsed around Christmas. He has since been on the new therapy – called belantamab mafodotin – as part of an early access weeks he was in remission. Other treatments could have left him isolating in his bedroom for months, so Paul says the therapy "is absolutely life-changing" and was "creating that opportunity to enjoy" life. Visiting Hadrian's Wall is next on the agenda for history buff Paul; and he's looking forward to one of his daughters graduating later this year. "Most people say 'you look really really well'... I have a good normal life," he told the BBC. How does this therapy work? Paul's therapy - belantamab mafodotin – is a lethal chemotherapy drug that has been bound to an antibody, similar to the ones the body uses to fight infection. However, these antibodies have been designed to spot markings on the outside of plasma cells. So they travel to cancerous cells, stick to the surface and are then absorbed. Once inside they release their toxic payload, to kill the cancer. The therapy is named Trojan horse therapy after the siege of the city of Troy in Greek mythology, when a giant wooden horse was used to smuggle soldiers into the cannot be cured, but clinical trials last year showed the Trojan horse therapy halted the cancer for three years, compared to 13 months with current therapies. Prof Peter Johnson, the national clinical director for cancer at NHS England, said the difference was "life-changing".He told me: "This is a really important development for people with myeloma, because although we may not be able to cure the illness, giving them time free of the disease and free of the symptoms is really important."We've seen in the last few years that using antibodies to deliver chemotherapy drugs directly into cells can make a big difference for a variety of different types of cancer." Around 33,000 people are living with myeloma in the UK. The new drug will be used when the first-choice therapy fails, so around 1,500 patients a year could decision comes after a review by the National Institute of Health and Care Excellence (NICE) concluded the drug was cost-effective for NHS use. NICE recommendations are normally adopted in England, Wales and Northern Ireland while Scotland has its own process. The therapy is kinder than other cancer treatments, but is not free from side-effects. After a cancer cell has been destroyed, the remaining chemotherapy drug will leak into the body. This can cause dry eyes and blurred vision. 'These are very smart drugs' The technical name for these drugs is an therapy was developed by GSK in the UK with early research taking place in Stevenage and the first clinical trials in Martin Kaiser, team leader in myeloma molecular therapy at the Institute of Cancer Research, said these "are very smart drugs" and the difference in side effects compared to other drugs "is really remarkable".While myeloma is still considered an incurable cancer, Prof Kaiser says drugs like this are "an important step towards a functional cure" and he thinks long-term remission will go "above 50% in the next five years".Antibody drug conjugates are being developed for a range of cancers. The limitation is being able to design an antibody that can target the cancer alone. There is one that can target some types of breast cancer. Research is already taking place on stomach and bowel McKinlay, from the charity Myeloma UK, said the approval would "transform the lives of thousands" and it was "fantastic to see the UK at the forefront of myeloma treatment".Health Minister Karin Smyth, said: "This ground-breaking therapy puts the NHS at the forefront of cancer innovation."
